Equity (Details) $ / shares in Units, vaccine_dose in Millions, $ in Millions		1 Months Ended
	Mar. 18, 2021 USD ($) vaccine_dose	Aug. 31, 2025 USD ($) $ / shares shares	Aug. 31, 2024 USD ($) shares	Jul. 31, 2024 USD ($) $ / shares shares	Sep. 30, 2025 $ / shares shares	Dec. 31, 2024 $ / shares shares	Mar. 01, 2021 $ / shares shares
Subsidiary, Sale of Stock [Line Items]
Common stock, par value (in USD per share)				$ 0.01	$ 0.01	$ 0.01
Warrant exercise price (in USD per share)					$ 1.64
Shares authorized (in shares) | shares				400,000,000
Common stock, shares authorized (in shares) | shares				390,000,000	390,000,000	390,000,000
Convertible preferred stock, shares authorized (in shares) | shares				10,000,000	10,000,000	10,000,000
Convertible preferred stock, par value (in USD per share)				$ 0.01	$ 0.01	$ 0.01
2024 Public Offering
Subsidiary, Sale of Stock [Line Items]
Number of shares issued under agreement (in shares) | shares				30,400,000
Common stock, par value (in USD per share)				$ 0.01
Price per share of shares issued under agreement (in USD per share)				$ 1.15
Proceeds from sale of shares issued under agreement | $				$ 32.3
Over-Allotment Option
Subsidiary, Sale of Stock [Line Items]
Number of shares issued under agreement (in shares) | shares			2,282,608	4,565,217
Option period purchase additional shares under agreement				30 days
Proceeds from sale of shares issued under agreement | $			$ 2.4
2025 Registered Direct Offering
Subsidiary, Sale of Stock [Line Items]
Number of shares issued under agreement (in shares) | shares		20,000,000
Price per share of shares issued under agreement (in USD per share)		$ 1.00
Proceeds from sale of shares issued under agreement | $		$ 18.5
2025 Registered Direct Offering | Registered Direct Offering Warrant
Subsidiary, Sale of Stock [Line Items]
Warrant to purchase common stock (in shares) | shares		20,000,000
Warrant exercise price (in USD per share)		$ 1.50
Warrant expiration date		2 years
Weighted average price of common stock, triggering warrants callable (in USD per share)		$ 2.50
Days during trading period triggering warrants callable (in USD per share)		5 days
Trailing trading days period triggering warrants callable (in USD per share)		30 days
COVAXIN Preferred Stock Purchase Agreement
Subsidiary, Sale of Stock [Line Items]
Convertible preferred stock, par value (in USD per share)							$ 0.01
Agreement to sell, number of shares issued in transaction (in shares) | shares							100,000
Agreement to sell, price per share (in USD per share)							$ 109.60
Advance payment amount | $	$ 6.0
Conversion ratio (in shares)							10
Supply agreement, number of doses | vaccine_dose	10.0